Corporate Member Update- Menarini Stemline- ELEGANT clinical trial listing MED-05207 11/24

ELEGANT clinical trial listing MED-05207  11/24

A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)

Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine therapy in participants with node-positive ER+/HER2- early breast cancer with high risk of recurrence. The main purpose of this study is to compare the Invasive Breast Cancer-Free Survival (IBCFS) over a period of up to 5 years. 4220 participants will be included in this study around the world. Participants will have equal chance to be assigned to receive either of the treatment combinations.

More info: Study Details | Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT) | ClinicalTrials.gov. 

Or email elegantstudy.com and/or click on below QR code